Trial reportImplementation science : IS2025
Implementation outcomes from the Hypertension Treatment in Nigeria program: results from a type 2 hybrid interrupted time series trial.
Trial report in Implementation science : IS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04158154 (Transforming Hypertension Treatment in Nigeria Using a Type II Hybrid, Interrupted Time Series Design), which is not on this map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Transforming Hypertension Treatment in Nigeria Using a Type II Hybrid, Interrupted Time Series Design
Who cites it
6 citing papers in PubMed.
- Telehealth Utilization and Patient Experiences: Patterns of Social Determinants of Health Among Individuals With Hypertension and Diabetes.JACC. Advances · 2026Article
- Impact evaluation of the Hypertension Treatment in Nigeria program using the Translational Science Benefits Model.Journal of clinical and translational science · 2026Article
- Identifying Digital Health Technology Engagement and Frustration Phenotypes in Patients with Multiple Chronic Conditions: Evidences from a Nationally Representative Cross-Sectional Study.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2026Article
- Implementation strategies for integrating non-communicable disease care into primary healthcare settings in sub-Saharan Africa: A systematic review.PLOS global public health · 2026Article
- Leveraging machine learning approach to identify relationships between practice facilitation strategies and practice characteristics based on the implementation research logic model.Implementation science communications · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundThe Hypertension Treatment in Nigeria Program was implemented across 60 primary healthcare centers (PHCs) in Nigeria to improve hypertension treatment and control using the World Health Organization's HEARTS package. This study reports the program's implementation outcomes.
methodsThe Hypertension Treatment in Nigeria Program used a type 2 hybrid interrupted time series design, and data were collected from January 2020 to December 2023. The RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) framework guided the evaluation, focusing on key metrics such as patients' and clinics' characteristics, prescription rate of fixed dose combination (FDC) drugs, medication availability, and retention.
resultsAmong 21,922 patients recruited (mean [SD] age = 49 [12], 68.1% female) from 60 primary healthcare centers (78.3% rural). Prescription of FDC increased from 16.3 (95% CI: 4.8%-27.8%) to 65.2% (95% CI: 64.0%-66.3%). The program distributed 336,116 30-day medication supplies, and nearly all (95%) PHCs had at least one 30-day supply of any BP-lowering medication in stock after the drug revolving fund implemented. The patient retention rate at 6 months increased between the pre-implementation to implementation periods from 59.9% to 63.1%.
conclusionsThe Hypertension Treatment in Nigeria Program successfully integrated hypertension services into Nigerian primary healthcare centers. Future efforts should focus on sustaining and scaling up the program's success.
trial registrationThe trial has been registered at www. CLINICALTRIALS: gov under NCT04158154.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.